Twist Bioscience Corporation (NASDAQ:TWST) investors will be delighted, with the company turning in some strong numbers with its latest results. Revenues beat expectations coming in atUS$89m, ahead of estimates by 2.0%. Statutory losses were somewhat smaller thanthe analysts expected, coming in at US$0.53 per share. This is an important time for investors, as they can track a company’s performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. So we gathered the latest post-earnings forecasts to see what estimates suggest is in store for next year.
Check out our latest analysis for Twist Bioscience
Taking into account the latest results, the consensus forecast from Twist Bioscience’s eleven analysts is for revenues of US$376.0m in 2025. This reflects a solid 14% improvement in revenue compared to the last 12 months. Losses are predicted to fall substantially, shrinking 39% to US$2.02. Yet prior to the latest earnings, the analysts had been forecasting revenues of US$373.1m and losses of US$2.26 per share in 2025. Although the revenue estimates have not really changed Twist Bioscience’sfuture looks a little different to the past, with a favorable reduction in the loss per share forecasts in particular.
There’s been no major changes to the consensus price target of US$54.59, suggesting that reduced loss estimates are not enough to have a long-term positive impact on the stock’s valuation. The consensus price target is just an average of individual analyst targets, so – it could be handy to see how wide the range of underlying estimates is. The most optimistic Twist Bioscience analyst has a price target of US$62.00 per share, while the most pessimistic values it at US$40.00. This shows there is still a bit of diversity in estimates, but analysts don’t appear to be totally split on the stock as though it might be a success or failure situation.
One way to get more context on these forecasts is to look at how they compare to both past performance, and how other companies in the same industry are performing. We would highlight that Twist Bioscience’s revenue growth is expected to slow, with the forecast 19% annualised growth rate until the end of 2025 being well below the historical 30% p.a. growth over the last five years. Juxtapose this against the other companies in the industry with analyst coverage, which are forecast to grow their revenues (in aggregate) 21% annually. Factoring in the forecast slowdown in growth, it looks like Twist Bioscience is forecast to grow at about the same rate as the wider industry.
